In binary classification applications, conservative decision-making that allows for abstention can be advantageous. To this end, we introduce a novel approach that determines the optimal cutoff interval for risk scores, which can be directly available or derived from fitted models. Within this interval, the algorithm refrains from making decisions, while outside the interval, classification accuracy is maximized. Our approach is inspired by support vector machines (SVM), but differs in that it minimizes the classification margin rather than maximizing it. We provide the theoretical optimal solution to this problem, which holds important practical implications. Our proposed method not only supports conservative decision-making but also inherently results in a risk-coverage curve. Together with the area under the curve (AUC), this curve can serve as a comprehensive performance metric for evaluating and comparing classifiers, akin to the receiver operating characteristic (ROC) curve. To investigate and illustrate our approach, we conduct both simulation studies and a real-world case study in the context of diagnosing prostate cancer.

Accurate and timely cancer diagnosis from histopathological slides is vital for effective clinical decision-making. This paper introduces DepViT-CAD, a deployable AI system for multi-class cancer diagnosis in histopathology. At its core is MAViT, a novel Multi-Attention Vision Transformer designed to capture fine-grained morphological patterns across diverse tumor types. MAViT was trained on expert-annotated patches from 1008 whole-slide images, covering 11 diagnostic categories, including 10 major cancers and non-tumor tissue. DepViT-CAD was validated on two independent cohorts: 275 WSIs from The Cancer Genome Atlas and 50 routine clinical cases from pathology labs, achieving diagnostic sensitivities of 94.11% and 92%, respectively. By combining state-of-the-art transformer architecture with large-scale real-world validation, DepViT-CAD offers a robust and scalable approach for AI-assisted cancer diagnostics. To support transparency and reproducibility, software and code will be made publicly available at GitHub.

The training and deployment of large language models (LLMs) create a feedback loop with human users: models learn human beliefs from data, reinforce these beliefs with generated content, reabsorb the reinforced beliefs, and feed them back to users again and again. This dynamic resembles an echo chamber. We hypothesize that this feedback loop entrenches the existing values and beliefs of users, leading to a loss of diversity and potentially the lock-in of false beliefs. We formalize this hypothesis and test it empirically with agent-based LLM simulations and real-world GPT usage data. Analysis reveals sudden but sustained drops in diversity after the release of new GPT iterations, consistent with the hypothesized human-AI feedback loop. Code and data available at https://thelockinhypothesis.com

The rising incidence of skin cancer, coupled with limited public awareness and a shortfall in clinical expertise, underscores an urgent need for advanced diagnostic aids. Artificial Intelligence (AI) has emerged as a promising tool in this domain, particularly for distinguishing malignant from benign skin lesions. Leveraging publicly available datasets of skin lesions, researchers have been developing AI-based diagnostic solutions. However, the integration of such computer systems in clinical settings is still nascent. This study aims to bridge this gap by employing a fusion of image processing techniques and machine learning algorithms, specifically neuro-fuzzy and colonial competition approaches. Applied to dermoscopic images from the ISIC database, our method achieved a notable accuracy of 94% on a dataset of 560 images. These results underscore the potential of our approach in aiding clinicians in the early detection of melanoma, thereby contributing significantly to skin cancer diagnostics.

Most people spend their lunch breaks grabbing a sandwich or going for a walk. But soon it could be possible to get a full-body MRI scan which detects the earliest stages of cancer during your lunch hour, thanks to AI. Health tech pioneer Ezra has launched its screening service in the UK, marking a major expansion beyond the US. Their AI-powered scans currently last an hour and cover 13 organs, with the added option of an extra lung CT scan and heart disease screening. As cancer rates are rising – especially among young people – the company say they are the best defence against the disease. With early detection, treatment can start earlier and prognosis improves dramatically.

The rapid advancement of deep learning (DL) has transformed healthcare, particularly in cancer detection and diagnosis. DL surpasses traditional machine learning and human accuracy, making it a critical tool for identifying diseases. Despite numerous reviews on DL in healthcare, a comprehensive analysis of its role in cancer detection remains limited. Existing studies focus on specific aspects, leaving gaps in understanding its broader impact. This paper addresses these gaps by reviewing advanced DL techniques, including transfer learning (TL), reinforcement learning (RL), federated learning (FL), Transformers, and large language models (LLMs). These approaches enhance accuracy, tackle data scarcity, and enable decentralized learning while maintaining data privacy. TL adapts pre-trained models to new datasets, improving performance with limited labeled data. RL optimizes diagnostic pathways and treatment strategies, while FL fosters collaborative model development without sharing sensitive data. Transformers and LLMs, traditionally used in natural language processing, are now applied to medical data for improved interpretability. Additionally, this review examines these techniques' efficiency in cancer diagnosis, addresses challenges like data imbalance, and proposes solutions. It serves as a resource for researchers and practitioners, providing insights into current trends and guiding future research in advanced DL for cancer detection.

Professionals increasingly use Artificial Intelligence (AI) to enhance their capabilities and assist with task execution. While prior research has examined these uses separately, their potential interaction remains underexplored. We propose that AI-driven training ("tutor" effect) and AI-assisted task completion ("tool" effect) can be complementary and test this hypothesis in the context of lung cancer diagnosis. In a field experiment with 336 medical students, we manipulated AI deployment in training, in practice, and in both. Our findings reveal that while AI-integrated training and AI assistance independently improved diagnostic performance, their combination yielded the highest accuracy. These results underscore AI's dual role in enhancing human performance through both learning and real-time support, offering insights into AI deployment in professional settings where human expertise remains essential.

Finding and diagnosing cancer is all about spotting patterns. Radiologists use x-rays and magnetic resonance imaging to illuminate tumors, and pathologists examine tissue from kidneys, livers, and other areas under microscopes. They look for patterns that show how severe a cancer is, whether particular treatments could work, and where the malignancy may spread. Visual analysis is something that AI has gotten quite good at since the first image recognition models began taking off nearly 15 years ago. Even though no model will be perfect, you can imagine a powerful algorithm someday catching something that a human pathologist missed, or at least speeding up the process of getting a diagnosis.

Breast cancer is one of the deadliest cancers causing about massive number of patients to die annually all over the world according to the WHO. It is a kind of cancer that develops when the tissues of the breast grow rapidly and unboundly. This fatality rate can be prevented if the cancer is detected before it gets malignant. Using automation for early-age detection of breast cancer, Artificial Intelligence and Machine Learning technologies can be implemented for the best outcome. In this study, we are using the Breast Cancer Image Classification dataset collected from the Kaggle depository, which comprises 9248 Breast Ultrasound Images and is classified into three categories: Benign, Malignant, and Normal which refers to non-cancerous, cancerous, and normal images.This research introduces three pretrained model featuring custom classifiers that includes ResNet50, MobileNet, and VGG16, along with a custom CNN model utilizing the ReLU activation function.The models ResNet50, MobileNet, VGG16, and a custom CNN recorded accuracies of 98.41%, 97.91%, 98.19%, and 92.94% on the dataset, correspondingly, with ResNet50 achieving the highest accuracy of 98.41%.This model, with its deep and powerful architecture, is particularly successful in detecting aberrant cells as well as cancerous or non-cancerous tumors. These accuracies show that the Machine Learning methods are more compatible for the classification and early detection of breast cancer.

Early screening for cancer has proven to improve the survival rate and spare patients from intensive and costly treatments due to late diagnosis. Cancer screening in the healthy population involves an initial risk stratification step to determine the screening method and frequency, primarily to optimize resource allocation by targeting screening towards individuals who draw most benefit. For most screening programs, age and clinical risk factors such as family history are part of the initial risk stratification algorithm. In this paper, we focus on developing a blood marker-based risk stratification approach, which could be used to identify patients with elevated cancer risk to be encouraged for taking a diagnostic test or participate in a screening program. We demonstrate that the combination of simple, widely available blood tests, such as complete blood count and complete metabolic panel, could potentially be used to identify patients at risk for colorectal, liver, and lung cancers with areas under the ROC curve of 0.76, 0.85, 0.78, respectively. Furthermore, we hypothesize that such an approach could not only be used as pre-screening risk assessment for individuals but also as population health management tool, for example to better interrogate the cancer risk in certain sub-populations.